CE-Iohexol

DRUG2 trials

Sponsors

CyDex Pharmaceuticals, Inc., Ligand Pharmaceuticals

Conditions

Contrast-induced NephropathyCoronary Angiography

Phase 2

Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography

WithdrawnNCT04627831

Ligand PharmaceuticalsContrast-induced Nephropathy

Start: 2022-01-31End: 2023-04-30Updated: 2022-04-11

Unknown Phase

Relative Bioavailability of CE-Iohexol (Captisol-enabled™ Iohexol) Injection and Omnipaque™ Injection

CompletedNCT03869983

CyDex Pharmaceuticals, Inc.Contrast-induced Nephropathy, Coronary Angiography

Start: 2019-04-12End: 2019-06-15Updated: 2019-08-16